Ratings Fresenius Medical Care AG Deutsche Boerse AG

Equities

FME

DE0005785802

Market Closed - Deutsche Boerse AG Other stock markets 03:30:56 2024-04-26 pm EDT			5-day change	1st Jan Change
37.4 ^EUR	-2.48%		+1.99%	-1.37%

Apr. 26	FMC FRESENIUS MEDICAL CARE AG & CO KGAA : Gets a Sell rating from Jefferies	ZD
Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT

Strengths

The company's profit outlook over the next few years is a strong asset.
The company's share price in relation to its net book value makes it look relatively cheap.
The company has a low valuation given the cash flows generated by its activity.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The group shows a rather high level of debt in proportion to its EBITDA.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
FRESENIUS MEDICAL CARE AG	-1.37%	11.72B		-
CVS HEALTH CORPORATION	-14.92%	84.68B		B-
HCA HEALTHCARE, INC.	+13.30%	81.12B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.71%	16.73B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.36B		A-
QUEST DIAGNOSTICS INCORPORATED	-2.63%	14.92B		A-
PURE HEALTH HOLDING	-31.75%	11.77B	-	-
DAVITA INC.	+27.44%	11.71B		B-
EUROFINS SCIENTIFIC SE	-3.97%	11.66B		A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes